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C a r o t i dD i s e a s ea n dS t r o k e .S t r o k ei sam a j o rc a u s eo f
disability, mortality, dementia, and depression in the world.
Carotid atherosclerosis is recognized as an important cause
of stroke and a modiﬁable factor for the risk reduction of
subsequent stroke. Randomized clinical trials have shown
eﬃcacyofcarotidendarterectomy(CEA)insecondarystroke
prevention. Carotid stenting has emerged as a new and
less invasive alternative to CEA. Continuous advances in
medical therapy have made remarkable success in stroke risk
reduction. These new treatment modalities were not widely
applied in most interventional trials, making extrapolation
of an optimal intervention strategy evermore complex
in patients with symptomatic and asymptomatic carotid
disease. The determination between “symptomatic” and
“asymptomatic” carotid stenosis is a pivotal determinant of
management of carotid disease. This special issue provides
an updated synopsis of risk factors, imaging modalities, and
diﬀerent treatment options of atherosclerotic carotid disease.
Some of the highlights are included in the following:
(i) Inthebasicscienceratmodel,theneurotrophiceﬀect
ofanimmunosuppressantagentaftertransientglobal
cerebral ischemia is presented by Z. N. Shariﬁ et al.
(ii) A paper of S. Kovacic and M. Bakran provides a dis-
cussion of the main genetic investigations associated
with human atherosclerotic vascular diseases.
(iii) The paper by A. Chatzikonstantinou et al. summa-
rizestheliteratureofthenaturalhistoryofthecarotid
disease and provides evidence that carotid stenosis is
a sensitive marker of systemic atherosclerosis.
(iv) The causal relationship between stroke-free patients
with advanced carotid stenosis and cognitive decline
is presented in the paper by I. Martini´ c-Popovi´ ce ta l .
(v) The paper by V. Vukovi´ c-Cvetkovi´ cp r e s e n t sac o m -
prehensive review of (microembolic signal) MES
detection and stroke risk by transcranial doppler
(TCD)—an important ultrasound technique shown
to successfully stratify asymptomatic patients at high
risk for future cerebrovascular events.
(vi) The paper by M. Roje-Bedekovic et al. explores the
visual evoked response in patients with severe carotid
stenosis, a marker which serves as an important
preoperative functional assessment of intracranial
circulation.
(vii) The paper by L. Pedrini et al. discusses near infrared
spectroscopy (NIRS) during CEA as a reliable meth-
od in detection of clamping ischemia and in the
prevention of clamping-related neurologic deﬁcits
during CEA.
(viii) In the paper by H. Koerner et al., periprocedu-
ral ischemic lesions on diﬀusion-weighted imaging
(DWI) during stenting procedures of supra-aortal
arteries are discussed. The level of platelet inhibition
ispresentedasanintriguingapproachtodetermining
the relationship between nonresponders to clopido-
grel and clinically silent microembolization.
(ix) The paper by F. Sallustio et al. presents a case series
data suggesting that early carotid artery stenting may
be considered as a safe alternative to CEA after IV2 Stroke Research and Treatment
thrombolysis in selected patients who are at high risk
of stroke recurrence.
The primary and secondary stroke prevention approach-
es are exciting clinical topics in evolution with many oppor-
tunities and options for both current treatment and future
discoveries.Innovationsingenetics,pharmacogenomics,and
vascular imaging will likely provide speciﬁc pathophysiolog-
ical targets, tailored treatments, and personalized medical
management for individuals with atherosclerotic carotid
disease. We hope that this special issue will serve as an
overview of the accomplishments, current practices, and
controversies in the ﬁeld as well as a useful reference for
management of patients with carotid disease and future
research opportunities.
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